PRELUDE THERAPEUTICS INC Operating Income
PRELUDE THERAPEUTICS INC (PRLD) reported Operating Income of -$15.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC operating income (loss) for the quarter ending 2026-06-30 was -$15.45M.
- PRELUDE THERAPEUTICS INC operating income (loss) for the quarter ending 2026-03-31 was -$14.18M.
- PRELUDE THERAPEUTICS INC operating income (loss) for the quarter ending 2025-12-31 was -$17.35M.
- PRELUDE THERAPEUTICS INC operating income (loss) for the quarter ending 2025-09-30 was -$20.42M.
- PRELUDE THERAPEUTICS INC operating income (loss) for fiscal 2025 was -$104.57M.
- PRELUDE THERAPEUTICS INC operating income (loss) for fiscal 2024 was -$139.71M.
- PRELUDE THERAPEUTICS INC operating income (loss) for fiscal 2023 was -$132.28M.
- PRELUDE THERAPEUTICS INC operating income (loss) for fiscal 2022 was -$123.54M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.45M 10-Q · filed 2026-08-11 | -$29.63M 10-Q · filed 2026-08-11 | -$46.98M derived: sum of 3 quarters · filed 2026-08-11 | -$67.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$14.18M 10-Q · filed 2026-05-12 | -$31.52M derived: sum of 2 quarters · filed 2026-05-12 | -$51.94M derived: sum of 3 quarters · filed 2026-05-12 | -$84.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$17.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$37.77M derived: sum of 2 quarters · filed 2026-03-10 | -$69.96M derived: sum of 3 quarters · filed 2026-08-11 | -$104.57M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$20.42M 10-Q · filed 2025-11-12 | -$52.61M derived: sum of 2 quarters · filed 2026-08-11 | -$87.22M 10-Q · filed 2025-11-12 | -$121.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$32.19M 10-Q · filed 2026-08-11 | -$66.80M 10-Q · filed 2026-08-11 | -$100.63M derived: sum of 3 quarters · filed 2026-08-11 | -$135.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$34.61M 10-Q · filed 2026-05-12 | -$68.44M derived: sum of 2 quarters · filed 2026-05-12 | -$102.81M derived: sum of 3 quarters · filed 2026-05-12 | -$139.98M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$33.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$68.21M derived: sum of 2 quarters · filed 2026-03-10 | -$105.37M derived: sum of 3 quarters · filed 2026-03-10 | -$139.71M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$34.38M 10-Q · filed 2025-11-12 | -$71.54M derived: sum of 2 quarters · filed 2025-11-12 | -$105.88M 10-Q · filed 2025-11-12 | -$143.26M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$37.16M 10-Q · filed 2025-08-14 | -$71.51M 10-Q · filed 2025-08-14 | -$108.89M derived: sum of 3 quarters · filed 2025-08-14 | -$142.27M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$34.34M 10-Q · filed 2025-05-06 | -$71.72M derived: sum of 2 quarters · filed 2025-05-06 | -$105.11M derived: sum of 3 quarters · filed 2025-05-06 | -$137.50M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$37.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$70.76M derived: sum of 2 quarters · filed 2025-03-10 | -$103.16M derived: sum of 3 quarters · filed 2025-03-10 | -$132.28M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$33.38M 10-Q · filed 2024-11-06 | -$65.78M derived: sum of 2 quarters · filed 2024-11-06 | -$94.90M 10-Q · filed 2024-11-06 | -$128.28M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$32.40M 10-Q · filed 2024-08-12 | -$61.51M 10-Q · filed 2024-08-12 | -$94.90M derived: sum of 3 quarters · filed 2024-08-12 | -$125.30M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$29.11M 10-Q · filed 2024-05-07 | -$62.50M derived: sum of 2 quarters · filed 2024-05-07 | -$92.91M derived: sum of 3 quarters · filed 2024-05-07 | -$122.37M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$33.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$63.79M derived: sum of 2 quarters · filed 2024-02-15 | -$93.25M derived: sum of 3 quarters · filed 2024-02-15 | -$123.54M 10-K · filed 2024-02-15 |
| 2022-09-30 | -$30.41M 10-Q · filed 2023-11-01 | -$59.87M derived: sum of 2 quarters · filed 2023-11-01 | -$90.16M 10-Q · filed 2023-11-01 | -$123.17M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$29.46M 10-Q · filed 2023-08-03 | -$59.75M 10-Q · filed 2023-08-03 | -$92.76M derived: sum of 3 quarters · filed 2023-08-03 | -$123.59M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$30.29M 10-Q · filed 2023-05-08 | -$63.30M derived: sum of 2 quarters · filed 2023-05-08 | -$94.13M derived: sum of 3 quarters · filed 2023-05-08 | -$122.06M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$33.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$63.85M derived: sum of 2 quarters · filed 2023-03-15 | -$91.77M derived: sum of 3 quarters · filed 2023-03-15 | -$113.73M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$30.84M 10-Q · filed 2022-11-14 | -$58.76M derived: sum of 2 quarters · filed 2022-11-14 | -$80.72M 10-Q · filed 2022-11-14 | -$100.17M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$27.92M 10-Q · filed 2022-08-09 | -$49.89M 10-Q · filed 2022-08-09 | -$69.33M derived: sum of 3 quarters · filed 2022-08-09 | -$87.48M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$21.97M 10-Q · filed 2022-05-10 | -$41.41M derived: sum of 2 quarters · filed 2022-05-10 | -$59.56M derived: sum of 3 quarters · filed 2022-05-10 | -$70.99M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$19.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$37.59M derived: sum of 2 quarters · filed 2022-03-17 | -$49.03M derived: sum of 3 quarters · filed 2022-03-17 | -$58.76M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$18.14M 10-Q · filed 2021-11-12 | -$29.58M derived: sum of 2 quarters · filed 2021-11-12 | -$39.32M 10-Q · filed 2021-11-12 | -$49.41M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$11.44M 10-Q · filed 2021-08-12 | -$21.17M 10-Q · filed 2021-08-12 | -$31.27M derived: sum of 3 quarters · filed 2021-08-12 | -$38.15M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$9.74M 10-Q · filed 2021-05-11 | -$19.83M derived: sum of 2 quarters · filed 2021-05-11 | -$26.72M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$16.98M derived: sum of 2 quarters · filed 2021-03-16 | -$28.11M 10-K · filed 2021-03-16 | |
| 2019-09-30 | -$6.88M 10-Q · filed 2020-11-10 | -$18.01M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |